Treatment of paediatric non-cystic fibrosis bronchiectasis

Abstract

Non-cystic fibrosis (CF) bronchiectasis, the abnormal dilatation of bronchial airways, is a heterogeneous condition caused by a variety of lung insults and results in significant morbidity and mortality. Although frequently reported as being an uncommon respiratory disease in the developed world, its impact on the respiratory health of specific populations has recently received increased attention. There are limited data on which to base management strategies. This article reviews the evidence for current treatment practices, provides an opinion on best practice, and discusses likely new therapies. Consideration is also given to the pharmacoeconomic hurdles that face the populations most affected.

• antibiotics
• bronchiectasis
• anticholinergics
• anti-inflammatory
• antileukotrienes
• bronchodilators
• chest physiotherapy
• children
• macrolides
• management
• methyl-xanthines
• mucolytics
• steroids
• surgery